ClinicalTrials.gg
Not yet recruitingNCT06926218Updated Apr 13, 2025

This Study is to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of HSK47388 in Healthy Volunteers

A Phase 1 interventional study of HSK47388 and Placebo in Healthy, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-13.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a single-center, randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability and PK of HSK47388 in healthy adult participants and preliminarily evaluate the PD of HSK47388

02

Conditions studied

  • Healthy

Keywords

  • HSK47388, Phase I
03

In context

Lead sponsor

Haisco Pharmaceutical Group Co., Ltd. is the lead sponsor of 118 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have given written before any study-related activities are carried out and must be able to understand the full nature and purpose of the study, including possible risks and adverse effects.
  2. Adult males and females between ≥ 18 and ≤ 55 years (inclusive) at Screening.
  3. Able and willing to attend the necessary visits to the study site

Exclusion criteria

Exclusion Criteria:

  1. Participants with any disease history that may affect the safety evaluation or in vivo process of IP as judged by the PI or delegate, including central nervous, cardiovascular, digestive, respiratory, urinary, blood, immune and endocrine diseases. Participants with childhood asthma (resolved) can be included at the discretion of the PI.
  2. Underlying physical or psychological medical condition that, in the opinion of the PI or delegate, would make the participant unlikely to comply with the protocol or complete the study per protocol.
  3. Participants who may not be able to complete the study for other reasons, cannot comply with the requirements of the study, or are unsuitable to participate in the study as judged by the PI or delegate.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    HSK47388

    Single oral doses of HSK47388

    Drug: HSK47388

  • Experimental
    placebo

    single oral dose of placebo

    Drug: Placebo

Interventions

  • cohort 1 to cohort 5

  • DrugPlacebo

    cohort 1 to cohort 5

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE

    The incidence, severity, and relationship to IP of AEs. Change from Baseline in clinical laboratory parameters (ie, hematology, serum chemistry, coagulation, and urinalysis parameters), physical examination findings, vital signs

    Time frame: 7 days after single dose

Secondary outcomes

  1. Cmax

    Maximum concentration

    Time frame: Predose up to Day 5 postdose

  2. Tmax

    Time to maximum concentration

    Time frame: Predose up to Day 5 postdose

  3. AUC

    Area under the drug concentrationtime curve

    Time frame: Predose up to Day 5 postdose

  4. t1/2

    Apparent terminal half-life

    Time frame: Predose up to Day 5 postdose

  5. CL/F

    Apparent total plasma clearance of drug

    Time frame: Predose up to Day 5 postdose

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2025; primary completion for Jul 2025, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2025
First posted
Apr 13, 2025
StartEst.
May 2025
Primary completionEst.
Jul 2025
CompletionEst.
Sep 2025
Last update
Apr 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06926218
Responsible party
Sponsor
First posted
Apr 13, 2025
Start date
May 2025 (estimated)
Primary completion
Jul 2025 (estimated)
Completion
Sep 2025 (estimated)
Last update
Apr 13, 2025

Study contacts

Redzepagic Emir
Contact
Emir.Redzepagic@cmax.com.au
0413231264

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK47388

Start the discussion